Prophylaxis of candidiasis in cancer patients
- PMID: 2191444
Prophylaxis of candidiasis in cancer patients
Abstract
Patients undergoing therapy for metastatic malignancies were randomly assigned to receive fluconazole or placebo as antifungal prophylaxis. Oropharyngeal candidiasis developed in 28% of 54 evaluable patients receiving placebo but in only 2% of 58 evaluable patients receiving fluconazole (P = .0003). Among patients receiving placebo, oropharyngeal candidiasis (thrush) occurred in 30% of those receiving antibiotic therapy and in 44% of those receiving adrenal corticosteroid therapy. Oropharyngeal candidiasis developed in 54% of the placebo patients who were colonized by Candida sp at the onset of prophylaxis. Fluconazole proved to be effective for prophylaxis of oropharyngeal candidiasis in susceptible patients and was well tolerated.
Similar articles
-
Prophylaxis of oropharyngeal candidiasis with fluconazole.Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S369-73. doi: 10.1093/clinids/12.supplement_3.s369. Rev Infect Dis. 1990. PMID: 2184514 Clinical Trial.
-
Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily.Arch Intern Med. 1991 Dec;151(12):2458-64. Arch Intern Med. 1991. PMID: 1747004 Clinical Trial.
-
Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS.Ann Intern Med. 1997 May 1;126(9):689-96. doi: 10.7326/0003-4819-126-9-199705010-00003. Ann Intern Med. 1997. PMID: 9139554 Clinical Trial.
-
Fluconazole once a week as secondary prophylaxis against oropharyngeal candidiasis in HIV-infected patients. A double-blind placebo-controlled study.Med J Aust. 1993 Mar 1;158(5):312-6. doi: 10.5694/j.1326-5377.1993.tb121784.x. Med J Aust. 1993. PMID: 8097273 Clinical Trial.
-
Fluconazole treatment of fungal infections in the immunocompromised host.Semin Oncol. 1990 Jun;17(3 Suppl 6):19-23. Semin Oncol. 1990. PMID: 2191443 Review.
Cited by
-
Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study.Support Care Cancer. 1995 Mar;3(2):139-46. doi: 10.1007/BF00365855. Support Care Cancer. 1995. PMID: 7773582 Clinical Trial.
-
A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group.Eur J Clin Microbiol Infect Dis. 1994 Apr;13(4):330-7. doi: 10.1007/BF01974614. Eur J Clin Microbiol Infect Dis. 1994. PMID: 7794307 Clinical Trial.
-
Routine versus selective antifungal administration for control of fungal infections in patients with cancer.Cochrane Database Syst Rev. 2014 Sep 4;2014(9):CD000026. doi: 10.1002/14651858.CD000026.pub2. Cochrane Database Syst Rev. 2014. PMID: 25188768 Free PMC article.
-
Prospective evaluation of effects of broad-spectrum antibiotics on gastrointestinal yeast colonization of humans.Antimicrob Agents Chemother. 1993 Jan;37(1):51-3. doi: 10.1128/AAC.37.1.51. Antimicrob Agents Chemother. 1993. PMID: 8431017 Free PMC article.
-
Interventions for preventing oral candidiasis for patients with cancer receiving treatment.Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD003807. doi: 10.1002/14651858.CD003807.pub3. Cochrane Database Syst Rev. 2007. PMID: 17253497 Free PMC article.